Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million on September 16, 2022. The acquisition was completed pursuant to an asset purchase agreement (the "APA") with Beatrice Society. Pursuant to the APA, the Company has issued a total of 22,500,000 common shares to the vendor which are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property.

Optimind Pharma Corp. (CNSX:OMND) completed the acquisition of MindSetting Inc. from Beatrice Society Inc. on September 16, 2022. Total consideration was CAD 1.35 million in stock.